Oncotelic's Novel Breast Cancer Treatment to Feature at San Antonio Symposium
TL;DR
Oncotelic's novel Sapu003 formulation offers a potential competitive advantage by overcoming limitations of existing mTOR inhibitors like Afinitor through improved bioavailability and tumor penetration.
Sapu003 is an intravenous formulation of everolimus developed through nanomedicine technology to address poor bioavailability and restricted tumor penetration issues of oral mTOR inhibitors.
This innovative cancer therapy could significantly improve treatment outcomes for HR⁺/HER2⁻ metastatic breast cancer patients, advancing the fight against high-unmet-need cancers.
Oncotelic will present three abstracts on its novel IV Deciparticle everolimus at the 2025 San Antonio Breast Cancer Symposium, showcasing clinical data from its ongoing Phase 1 trial.
Found this article helpful?
Share it with your network and spread the knowledge!
Oncotelic Therapeutics, Inc. announced that three abstracts featuring its investigational intravenous Deciparticle everolimus have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium in San Antonio, Texas. The abstracts detail clinical rationale, molecular biomarkers, and pharmacokinetic data supporting the ongoing Phase 1 trial in HR⁺/HER2⁻ metastatic breast cancer. This development represents a significant advancement in addressing treatment limitations for patients who have developed resistance to standard therapies.
Developed by Sapu Nano—a joint venture between Oncotelic and Dragon Oversea—Sapu003 represents a novel IV formulation of everolimus specifically designed to overcome the limitations of oral mTOR inhibitors such as Afinitor. These limitations include poor bioavailability and restricted tumor penetration, which have historically challenged effective treatment outcomes in metastatic breast cancer patients. The acceptance of these three abstracts at one of the world's premier breast cancer conferences underscores the scientific community's interest in this innovative approach to mTOR inhibition.
The significance of this development lies in addressing critical treatment gaps for HR⁺/HER2⁻ metastatic breast cancer patients who have developed resistance to standard therapies. Current oral mTOR inhibitors face substantial pharmacokinetic challenges that limit their clinical effectiveness, particularly in achieving adequate drug concentrations at tumor sites. The Deciparticle formulation aims to bypass these limitations through intravenous administration, potentially offering improved therapeutic outcomes for patients with limited treatment options.
Oncotelic Therapeutics maintains an active newsroom where investors and interested parties can follow developments. The company's broader communications strategy includes specialized platforms like InvestorWire, which provides advanced wire-grade press release syndication services detailed at https://www.InvestorWire.com. These platforms help ensure that important scientific and corporate developments reach appropriate audiences within the investment and medical communities.
The upcoming presentations at the San Antonio Breast Cancer Symposium will provide the oncology community with critical insights into the pharmacokinetic profile and biomarker strategy for Sapu003. This data could potentially reshape treatment approaches for metastatic breast cancer patients who have exhausted conventional therapeutic options. The symposium acceptance represents an important milestone in the clinical development pathway for this investigational therapy, bringing it closer to potential regulatory review and eventual patient access if clinical trials demonstrate safety and efficacy.
Curated from InvestorBrandNetwork (IBN)
